Cisplatin und Epirubicin bei rezidivierendem oder primär progredientem Ovarialkarzinom

Conference paper


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Advancer Ovarian Cancer Group Trialist Group: Chemotherapy in advanced ovarian cancer: An overview of randomized trials BMJ. 303, 884–893, 1991CrossRefGoogle Scholar
  2. 2.
    Spielmann, M., Kerbat, P., Delozier, T. et al.: Pirarubicin in advanced breast cancer: A french cooperative phase II study Eur. J. Cancer 26, 821–823, 1990PubMedCrossRefGoogle Scholar
  3. 3.
    Bronchud, M.H., Howell, A., Crowther, D., Hopwood, P., Souza, I., Dexter, T.M.: The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast cance and ovarian cancer Br. J. Cancer 60, 121–125, 1989PubMedCrossRefGoogle Scholar
  4. 4.
    Du Bois, A., Meerpohl, H.G., Vach, H., Kommos, F.G.M., Fenzel, E., Pfleiderer, A.: Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-rpretreated patients: a study with ondansetron Eur. J. Cancer 28, 450–457, 1992PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • P. Dall
    • 1
  1. 1.Universitäts-Frauenklinik FreiburgFreiburg i. Br.Deutschland

Personalised recommendations